

509,144
Rec'd PCT TO 27 SEP 2004

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

10/509144

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 October 2003 (02.10.2003)

PCT

(10) International Publication Number
WO 03/080862 A1

(51) International Patent Classification⁷: C12Q 1/68

(21) International Application Number: PCT/EP03/03104

(22) International Filing Date: 25 March 2003 (25.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
102 14 232.7 25 March 2002 (25.03.2002) DE

(71) Applicant (for all designated States except US): EPIGENOMICS AG [DE/DE]; Kastanienallee 24, 10435 Berlin (DE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): BERLIN, Kurt [DE/DE]; Marienkäferweg 4, 14532 Stahnsdorf (DE).

(74) Agent: SCHUBERT, Klemens; Neue Promenade 5, 10178 Berlin-Mitte (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD AND DEVICES FOR DNA METHYLATION ANALYSIS



(57) Abstract: The invention outlines a method for the methylation pattern retaining amplification of nucleic acid molecules. Furthermore the invention describes several devices for use in the methylation pattern retaining amplification of nucleic acid molecules.



WO 03/080862 A1

Method and devices for DNA methylation analysis

Field of the invention

5 The analysis of methylation of genomic DNA is proving to be of increasing importance. Aberrant genomic methylation patterns have been shown to be implicated in a wide range of disease conditions, including cancer. DNA methylation analysis requires the development of a range of tools
10 specific to the detection of DNA methylation as conventional techniques such as PCR and sequencing are not capable of distinguishing 5-methyl cytosine from unmethylated cytosine.

15 Prior Art

The most common covalent modification of genomic DNA is the methylation of cytosine to 5 methyl cytosine. In eukaryotic cell systems the bulk of methylation activity takes place during the S phase of the cell cycle. Complex
20 tissue specific methylation patterns established during development are preserved in newly replicated DNA by the action of maintenance methyltransferases. These enzymes act to methylate genomic DNA that has been semiconservatively replicated. The methyl transfer reaction proceeds
25 through a non specific binding of the transferase to the hemimethylated DNA strand, identification of the target base followed by the recruitment of the methyl donor group, most commonly S-adenosyl-L-methionine (AdoMet) to the active site. DNA methyltransferases (m5C Mtase) attach a methyl group to the 5 position carbon. The reaction is carried out via a covalent intermediate between
30 the enzyme and the base whereby the target cytosine is flipped through 180 degrees. The mechanism of methyltransferase dependant cytosine methylation is further reviewed in articles such as Cheng and Roberts 'AdoMet-

35

dependant methylation, DNA methyltransferases and base flipping' Nucleic Acids Res. 15;29(18):3784-95.

5 Several species of methyltransferases have been identified, of particular interest to this invention are the family of maintenance methyltransferases that propagate the methylation pattern of hemimethylated DNA within the unmethylated strand, such as Dnmt1. The in vitro action mechanism of DNMT1 is fully discussed in Pradhan, S., Bacolla, A., Wells, R. D., Roberts, R. J. . 'Recombinant Human DNA (Cytosine-5) Methyltransferase. I. Expression, Purification and comparison of de novo and maintenance methylation.' J. Biol. Chem. 274: 33002-33010 and Bacolla A, Pradhan S, Roberts RJ, Wells RD. 'Recombinant human DNA (cytosine-5) methyltransferase. II. Steady-state kinetics reveal allosteric activation by methylated DNA' J Biol Chem. 12;274(46):33011-9.

20 Cytosine methylation plays an important role in gene expression and regulation and has been shown to be critical in the maintenance of normal cellular functions. It is associated with genomic imprinting, embryonic development and a wide variety of diseases, including cancer.

25 For example, aberrant DNA methylation within CpG islands is common in human malignancies leading to abrogation or overexpression of a broad spectrum of genes (Jones, P.A. Cancer Res 65:2463-2467, 1996). Abnormal methylation has also been shown to occur in CpG rich regulatory elements in intronic and coding parts of genes for certain tumours (Chan, M.F., et al., Curr Top Microbiol Immunol 249:75-86,2000). Using restriction landmark genomic scanning, Costello and coworkers were able to show that methylation patterns are tumour-type specific (Costello, J. F., et al., Nat Genet 24:132-138, 2000). Highly characteristic DNA methylation patterns could also be shown for breast

cancer cell lines (Huang, T. H.-M., et al., Hum Mol Genet 8:459-470, 1999). Genome wide assessment of methylation status represents a molecular fingerprint of cancer tissues.

5

Therefore it follows that the analysis of methylation patterns within genomic DNA is of considerable importance. However, 5-methylcytosine analysis currently cannot be carried out using standard molecular biological tool. 5-methylcytosine has the same base pairing behaviour as unmethylated cytosine therefore it cannot be identified by sequencing. Moreover, the epigenetic information carried by 5-methylcytosine is completely lost during PCR amplification. Current methods of analysis are generally carried out using one of two methods. Firstly, methylation sensitive restriction enzyme digest, and secondly by the more versatile technique of bisulphite treatment followed by PCR analysis.

10

15

20

25

30

35

Bisulphite treatment followed by alkaline hydrolysis converts cytosine within a nucleic acid sample to uracil. The treatment is highly specific in that 5-methylcytosine remains unconverted. Thus PCR amplification of the treated DNA results in the synthesis of amplificate nucleic acids wherein thymine is substituted for unmethylated cytosine within the original genomic sequence. The bisulphite treatment is often carried out on minute quantities of genomic DNA which may be lost during handling. The sensitivity of the technique is improved by use of an agarose matrix within which the DNA is enclosed thus preventing the diffusion and renaturation of the DNA (bisulphite only reacts with single-stranded DNA), and which replaces all precipitation and purification steps with fast dialysis (Olek A, Oswald J, Walter J. A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res. 1996 Dec 15;24(24):5064-6).

In practice the utility of the bisulphite treatment is often limited by the sensitivity of the technique to small samples. Furthermore, the requirement of the agarose step in order to limit DNA loss reduces the suitability of the technique to automatization.

Methods for the amplification of specific DNA targets are based upon template directed primer extension by polymerases. The most widely utilised of these methods is the polymerase chain reaction 'PCR' (Mullis, K. et al., Cold Spring Harbor Symp. Quant. Biol. 51:263-273 (1986); Erlich H. et al., EP 50,424; EP 84,796, EP 258,017, EP 237,362; Mullis, K., EP 201,184; Mullis K. et al., U.S. Pat. No. 4,683,202; Erlich, H., U.S. Pat. No. 4,582,788; Saiki, R. et al., U.S. Pat. No. 4,683,194 and Higuchi, R. "PCR Technology," Ehrlich, H. (ed.), Stockton Press, NY, 1989, pp 61-68).

In the polymerase chain reaction successive cycles of denaturation are followed by annealing and polymerisation. In the first step the DNA double helix is denatured by transient heating. This is followed by the annealing of two species of primers, one to each strand of DNA. Subsequently the annealed primers are extended using a polymerase. This is followed by the denaturation of the resultant double stranded nucleic acids, allowing each strand to serve as a template for another cycle of template directed primer extension.

The polymerase chain reaction (hereafter PCR) is most commonly performed in disposable reaction tubes such as small, plastic microcentrifuge tubes or test tubes which are placed in an instrument containing a thermally controlled heat exchanger. Examples of these instruments are disclosed in U.S. Pat. No. 5,038,852, U.S. application Ser. No. 07/709,374, filed Jun. 3, 1991, and U.S. appli-

cation Ser. No. 07/871,264, filed Apr. 20, 1992. Alternative devices for the PCR analysis of nucleic acids wherein the reaction is carried out in capillary tubes have been described in U.S. Pat. No. 5,779,977 .

5

The heat exchanger in these instruments is typically a metal block; however, hot air ovens and water baths also have been used. The temperature of the reaction mixture in the reaction tubes is changed in a cyclical fashion to cause denaturation, annealing and extension reactions to occur in the mixture. Three separate incubation temperatures commonly were used in the first generation PCR thermal cycling applications. These were typically around 94.degree. C. for denaturation, around 55.degree. C. for annealing, and around 72.degree. C. for extension. More recently, the annealing and extension incubations have frequently been combined to yield a two temperature incubation process, typically around 94.degree. C. for denaturation, and around 50.degree.-65.degree. C. for an annealing and extension incubation. The optimal incubation temperatures and times differ, however, with different targets and primer oligonucleotides.

Description

The invention relates to a method and devices for the enzymatic amplification of nucleic acids whereby the methylation pattern of said nucleic acid is conserved in the amplificate sequence. The method presents improvements over the basic polymerase chain reaction in that a further methylation step is carried out thereby conserving the complex methylation pattern of a genomic DNA in the amplificate nucleic acids. Subsequent to each cycle of the polymerase chain reaction, the hemimethylated nucleic acid is contacted with a maintenance methyltransferase thereby allowing for the methylation of the unmethylated strand of the nucleic acid. Methylation of the hemimethy-

lated DNA by a maintenance methyltransferase is such that the specific methylation pattern of the CpG dinucleotides within the template strand of the nucleic acid is replicated in the unmethylated strand. The described invention
5 thereby allows for the preservation of complex genomic methylation patterns within amplificate nucleic acids.

The maintenance of complex methylation patterns within nucleic acid amplicates allows for the analysis of sam-
10 ples using a variety of methylation specific techniques. Such techniques, which include bisulphite analysis and methylation sensitive restriction enzyme digest were heretofore carried out using limited amounts of DNA sam-
15 ples and/or in combination with a polymerase chain reaction.

Definitions

The following terms and phrases as used herein are intended to have the meanings as described below.

20

In the context of the present invention the term 'methylation pattern' is taken to mean the specific consecution of 5 methyl cytosine within a nucleic acid sequence.

25

In the context of the present invention the term 'template nucleic acid' refers to a single stranded nucleic acid which serves as a template for the synthesis of a nucleic acid from a primer oligonucleotide.

30

In the context of the present invention the term 'synthesised nucleic acid' is taken to mean a nucleic acid which is the product of a template directed primer extension reaction.

35

The invention comprises method and devices for the methylation pattern retaining enzymatic amplification of nu-

cleic acids. The method comprises a modified form of the polymerase chain reaction, wherein an additional methylation step during each cycle of the reaction allows for the replication of complex methylation patterns present within a genomic DNA sample in amplificate nucleic acids. The method comprises four steps of which the first three steps are known in the art, for example, in US patents numbers 4,683,195, 4,683,202, and 4,800,159. The fourth step is the novel methylation retaining step.

It is one object of the present invention to provide a method for the amplification of genomic DNA whereby the cytosine methylation pattern of the genomic DNA is retained in the amplificate sequence(s), said method comprising the following steps:

(a) heating the genomic DNA to a temperature operative to cause denaturation

(b) cooling the denatured DNA in the presence of single stranded oligonucleotide primers such that the primers anneal to the DNA

(c) heating the mixture in the presence of a polymerase and nucleotides to a temperature such that the primers are extended

(d) contacting the double stranded nucleic acid with a methyltransferase and a methyl donor molecule under conditions conducive to the methylation of the synthesised strand such that the CpG dinucleotides within the synthesised strand are methylated according to the methylation status of the corresponding CpG dinucleotide on the template strand thereby preserving the genomic methylation pattern

(e) repeating steps A-D a desired number of times to reach a desired number of nucleic acids.

In a preferred embodiment of the present invention the methyltransferase is a maintenance methyltransferase. In

a further preferred embodiment the methyltransferase is DNA (cytosine-5) Methyltransferase (DNMT 1).

5 According to the invention it is preferred that the methyl donor molecule is S-adenosylmethionine.

10 It is also preferred according to the invention that the methyl group carries a detectable label which is incorporated into the synthesised nucleic acid strand.

In a further preferred embodiment of the present invention a plurality of primer oligonucleotides are immobilised on a solid surface.

15 It is also preferred that the methyltransferase is immobilised on a solid surface.

20 According to the invention it is also preferred that the polymerase is immobilised on a solid surface.

In another preferred embodiment of the present invention a further step (f) is present that is a treatment with an agent capable of distinguishing between methylated and unmethylated cytosine bases. Hereby it is preferred that
25 the agent is a methylation sensitive restriction enzyme. It is especially preferred according to the invention that the agent is a bisulphite solution.

30 Another object of the invention is a device for the methylation pattern retaining amplification of nucleic acids according to Claim 1 said device comprising two or more reaction chambers, channel means providing fluid connections between adjacent chambers and the first and last reaction chambers, temperature regulating means for
35 controlling the temperature of each reaction chamber.

It is preferred according to the invention that the device for the methylation pattern retaining amplification of nucleic acids comprises two vessels, a reaction chamber, temperature regulating means for controlling the temperature of the reaction chamber, means for transferring liquid reagent from the first and second vessels to the reaction chamber, channel means providing fluid connections between adjacent chambers and the first and last reaction chambers means for draining liquid reagents from the reaction chamber.

A nucleic acid obtained according to the method of the invention by optionally using the device according to the invention.

A further object of the present invention is a method of manufacturing a methylated nucleic acid according to the method of the invention by optionally using the device according to the invention.

The details of method of the present invention are as follows.

In the first step of the method (hereinafter referred to as Step A) the sample DNA is heat denatured allowing the single stranded DNA to be used in the analysis, suitable melting temperatures are dependant upon several variables including GC content of the sequence and length of sequence, but in general may be 95°C or higher for 15 seconds to 2 minutes. In the second step (hereinafter referred to as Step B) oligonucleotide primers are annealed to the template sequence at a lower temperature, (typically between 40°C and 60°C for 30 to 60 seconds), again dependant upon the GC content and length of the primers. The oligonucleotides are able to form stable associations ('anneal') with the single stranded DNA (hereinafter re-

ferred to as the template strand) and thus serve as primers for nucleic acid synthesis by a DNA polymerase. In the third step (hereinafter referred to as Step C) a corresponding nucleic acid strand to the template is synthesised from the primer oligonucleotide by means of the polymerase and deoxynucleotide triphosphates (dNTPs). The temperature is raised to an optimum for the polymerase, which in the case of commonly used thermostable polymerases is approximately 74°C, primer extension then lasts approximately 1 to 2 minutes. These steps are all common to the polymerase chain reaction. Reactions take place in a mixture which includes a sample of the target DNA, a thermostable DNA polymerase, oligonucleotide primers, deoxynucleotide triphosphates (dNTPs), reaction buffer, magnesium and optional additives. Reaction temperatures and times must be optimised according to factors including, for example, GC content and length of sequence and primers.

Subsequent to enzymatic amplification, the resultant hemimethylated nucleic acid is enzymatically methylated according to the methylation status of the CpG dinucleotides within the template strand. The enzyme should be a maintenance methyltransferase with an affinity for hemimethylated DNA .

This step is executed a user defined number of times. Each repetition of Steps A-D results in a doubling of the number of nucleic acid molecules within the sample. The exponential increase in the quantity of synthesised nucleic acid enables the production of sufficient quantities of methylated nucleic acids for use in other methylation specific analysis techniques such as methylation sensitive restriction enzyme analysis and bisulphite treatment with a greatly increased efficiency.

Suitable methylation enzymes for use in Step D of the method are limited to those capable of methylating the cytosine at the 5 position according to the methylation status of the cytosine within the corresponding CpG dinucleotide on the template strand. In the case of a cytosine within a CpG upon the template strand being methylated, then the corresponding CpG to which it is hybridised on the synthesised strand will be methylated by action of the enzyme at the 5 position of the cytosine base. If the cytosine within said CpG is unmethylated then the corresponding CpG on the synthesised strand will remain unmethylated. The reaction is carried out using appropriate buffers and other reagents and reaction conditions as recommended by the supplier of the enzyme, this may include a methyl donor molecule such as, but not limited to S-adenosylmethionine. Furthermore said methyl group may carry a detectable label, for example a fluorescent label.

The enzyme may be from any source e.g. Human, Mouse, recombinant. In a preferred embodiment the enzyme is DNA Methyltransferase 1 (DNMT1). In a further preferred embodiment the methyltransferase is immobilised upon a solid surface.

The invention further relates to devices for the methylation retaining amplification of a DNA sequence. Several embodiments of devices for the methylation retaining PCR of nucleic acids are envisioned. All devices described herein are controlled by a user defined protocol implemented by a programmable computer. The computer is capable of controlling all variables of the system including sample handling, flow, velocity, pressure, and temperature. Differences between said embodiments arise due to the different means of heating and cooling the reaction

mixture and also the alternative means employed for contacting the reagents.

Three embodiments of such devices are described below.

5

Multiple reaction chamber methylation retaining PCR device

A first embodiment of a methylation retaining PCR device is illustrated in Figure 1, said embodiment is hereinafter referred to as Device 1. The illustrated embodiment has four thermostated units. Each unit comprises a means for temperature maintenance (1), reaction chamber for containing the reaction solution (2), said reaction chambers connected by tube means (3) for transporting the reaction solution between the reaction chambers and further comprising means for introducing additional reagents into the reaction solution. Two of the reaction chambers may further each comprise a solid support (4) upon which is immobilised the enzymatic means for carrying out Steps C or D of the reaction respectively. In a further preferred embodiment the reaction chamber within which Step C is carried out does not further comprise a solid surface upon which the polymerase is immobilised, the polymerase is a component of the reaction solution. The reaction chambers are each connected by tube means in order to transport the reaction solution between each chamber. Transport through the tubes is carried out by means of a pump(6) , preferably a peristaltic pump. The tubes further comprise valves ensuring that the reaction solution flows in a unidirectional manner. In a further preferred embodiment the pump mechanism may be a plunger and seal arrangement, similar to a syringe. Said pump may be connected to a first reaction chamber within which the initial denaturation reaction takes place. The pump mechanism is under control of a computer programmed to carry out the PCR protocol. The pump or plunger is activated

10

15

20

25

30

35

back and forth to draw reaction mixture into the reaction chamber,

5 In a first reaction chamber, Step A of the reaction is carried out whereby the methylated nucleic acid sample is heat denatured in a reaction solution further containing necessary buffers and reagents. Said reaction chamber is kept at a consistent suitable temperature, generally between 85°C and 95°C. The reaction mixture is then passed
10 to the second reaction chamber in order to carry out Step B of the reaction. The second reaction chamber is kept at a consistent temperature suitable for the annealing of primer oligonucleotides to the target DNA. Said temperature is dependant upon the composition of the primers but
15 a general estimate may be calculated using the formula $T_m = 81.5 + 16.6 \times (\log_{10}[\text{Na}^+]) + 0.41 \times (\%G+C) - 675/n$ wherein $[\text{Na}^+]$ is the molar salt concentration; $[\text{K}^+] = [\text{Na}^+]$ and n = number of bases in the oligonucleotide. Step B according to Claim 1 is carried out in the second chamber.
20 ber.

Upon annealing of the primer oligonucleotides the reaction mixture is passed to the third reaction chamber whose temperature is regulated to that suitable for the
25 action of the polymerase used in the method. In the case of the commonly used Taq polymerase this would be 74°C.

As taught by Kim and Smithies (Nucleic Acids Research 16, 8887-8903) incubation at the intermediate "extension"
30 temperature is unnecessary. Accordingly only two temperatures are required one in the range from 37-72.degree. C. for annealing and extension and one in the 85-98.degree. C. range for denaturation. Therefore, a further embodiment of Device 1 may consist of only three chambers
35 wherein chambers 2 and 3 are replaced by a single cham-

ber, said chamber further comprising a solid support upon which the polymerase is immobilised.

5 Subsequent to primer extension the reaction mixture is passed to a fourth reaction chamber for Step D. Said reaction chamber further comprises a solid phase upon which a methyltransferase is immobilised. At this stage the required co factor for the methyltransferase (e.g. S-adenosylmethionine) is added to the reaction solution.

10 The reaction mixture is passed through the reaction chamber such that the hemimethylated double stranded nucleic acids are contacted with the methyltransferase enzyme sufficient for the methylation of all nucleic acids within the reaction mixture. Reaction times and conditions are calculated and optimised according to the methyltransferase as well as CpG composition of the amplify-

15 cate nucleic acids. The reaction solution is then passed back to the first reaction chamber allowing Steps A-D to be repeated until the desired quantity of amplicates is synthesised.

20

In its simplest form, the thermostatic means described in the inventions above may comprise two metal block heat exchangers separated by a layer of insulation. The heat exchangers could also be other types of heat exchangers such as thermostatically controlled constant temperature fluid baths. Each metal block heat exchanger is preferably made of aluminium or some other good heat conducting metal to minimise temperature gradients therein.

25

30 The temperature of each metal block is maintained at a constant temperature by any suitable temperature control system. A suitably programmable control system which may be used is disclosed in U.S. Pat. No. 5,038,852 and in U.S. Patent application No. 07/871,264, filed Apr. 20, 1992.

35

Peltier devices are ideal for controlling the temperatures of the metal blocks because these metal block heat exchangers are each maintained at a constant temperature. Suitable known temperature sensing and feedback control circuits (not shown) are necessary to control the direction of current flow through the Peltier devices to maintain the block temperature constant by extracting heat from the block when it gets too hot and adding heat when it gets too cold. Any other temperature control system will also work for the blocks such as resistance heaters and/or heated/chilled fluid circulating through passages in the metal blocks with the chilled fluid being, for example, tap water or antifreeze chilled by circulating Freon of a refrigeration unit, depending upon the desired temperatures of the blocks.

Sample handling and reaction conditions, including, flow, velocity, pressure, and temperature are all controlled according to a user defined protocol by a computer (5). Connections between said computer and components of the device illustrated by, but not limited to, dotted lines.

Single reaction chamber methylation retaining PCR device

In a further embodiment of a methylation retaining PCR device (hereinafter referred to as Device 2), all steps of the method are carried out in one reaction chamber. The device comprises a thermocycling reaction chamber (10), two vessels (7) containing reagents (8) required for the different stages of the procedure. The reaction chamber is thermostatically cycled between temperatures suitable for Steps A, B C and D of the reaction as described above.

In said embodiment the apparatus comprises 2 vessels (7) and a reaction chamber (10). The vessels are each con-

5 nected to the reaction chamber by tube means (11), reaction solution is passed through the tubes by means of a pump (12), preferably a peristaltic pump. The tubes further comprise valves (9) ensuring that the reaction solution flows in a unidirectional manner. A first vessel contains all reagents necessary for Steps A to C according to Claim 1 for example, but not limited to, dNTPs, reaction buffer and polymerase. A second vessel contains all reagents necessary for Step D for example, but not limited to, reaction buffer, methyltransferase and co-factors. The reaction chamber is a thermocycling vessel comprising a solid surface (13) upon which an excess of primer oligonucleotides required during Step B of the reaction are immobilised. Sample DNA and reagents from the first vessel are passed into the reaction chamber where the denaturation, annealing and extension processes (Steps A-C) are carried out. Primer oligonucleotides immobilised upon a solid surface hybridise to a genomic DNA during Step B of the first cycle of the reaction. Single stranded nucleic acid molecules generated by Step A of the reaction hybridise to the primer oligonucleotides. After extension (Step C), methylation (Step D) and denaturation (Step A) the single stranded template nucleic acids hybridise to unused primer oligonucleotides in the vicinity of the primer oligonucleotides to which they were hybridised in the previous cycle.

30 Upon completion of the extension (Step C) and prior to the methylation reaction (Step D) the reaction mixture is drained from the reaction chamber by means of an outlet (15). Said outlet may further comprise a valve and pump mechanism (12) as illustrated. Reagents from the second vessel are passed into the reaction chamber and methylation of the hemimethylated nucleic acids is carried out under appropriate conditions. The reaction chamber may then be drained of reagents allowing reagents from the

first vessel to be passed into the reaction chamber and allowing Steps A to D of the reaction to proceed again until the desired quantity of methylated nucleic acids is synthesised.

5

Sample handling and reaction conditions, including, flow, velocity, pressure, and temperature are all controlled according to a user defined protocol by a computer (14). Connections between said computer and components of the device illustrated by, but not limited to, dotted lines.

10

In one embodiment of the invention (e.g. Device 1) the polymerase and methylase enzymes as used in Steps C and D of the reaction may be immobilised upon a solid support.

15

In a further embodiment (e.g. Device 2) primer oligonucleotides as utilised in Step C of the method are required to be immobilised upon a solid support. The solid support may be beads, particles, sheets, dipsticks, rods, membranes, filters, fibres (e.g., optical and glass), and suchlike. Preferably, the solid support is a bead. The material composition of the solid support includes, but is not limited to, polystyrene, nitrocellulose, plastic, nylon, glass, silica, metal, metal alloy, polyacrylamide, polyacrylate, crosslinked-dextran and combinations thereof. Preferably, the solid support is thermally stable (e.g., able to withstand temperatures of up to 100.degree. C.) to withstand thermocycling conditions as described in the invention. Preferably, the solid support is capable of being modified by the attachment of oligonucleotide primers. Methods for the immobilisation of oligonucleotides are known in the art and include the use of photolabile groups and solid phase chemistry (U.S. Patent 5,744,305). Methods for the immobilisation of enzymes are also well known in the art for example in 'Immobilization of Enzymes and Cells' Bickerstaff and Walker, Humana Press 1996.

20

25

30

35

Double reaction chamber methylation retaining PCR device

A third embodiment of a methylation retaining PCR device is illustrated in Figure 3, said embodiment is hereinafter referred to as Device 3. The illustrated embodiment of the device has two reaction chambers. A first reaction chamber comprises a thermocycling unit (16) and a vessel (17) for containing the reaction solution. Steps A to C of the reaction are carried out in this chamber. The reaction solution is then pumped from the first reaction chamber to a second reaction chamber (18) using tube means (19) wherein Step D of the method is carried out. Reagents required for Step D of the reaction are contained in a vessel (20) which is connected to reaction chamber (18) by tube means. Reagents from the vessel (20) are pumped into reaction chamber (18) by tube means (21). The pump (22) may take in form standard in the art, for example a peristaltic pump. However, particularly preferred is a syringe pump.

Sample handling and reaction conditions, including, flow, velocity, pressure, and temperature are all controlled according to a user defined protocol by a computer (23). Connections between said computer and components of the device illustrated by, but not limited to, dotted lines.

Thermocycling units suitable for use in nucleic acid amplification techniques are known in the art and commercially available, for example, from manufacturers such as Perkins Elmer and Eppendorf.

FiguresFigure 1

Figure 1 illustrates a multiple reaction chamber methylation retaining PCR device.

Figure 2

Figure 2 illustrates a single reaction chamber methylation retaining PCR device.

5

Figure 3

Figure 3 illustrates a double reaction chamber methylation retaining PCR device.

10

ExamplesExample 1

Genomic DNA commercially available from Promega is used in the analysis. A CpG rich fragment of the regulatory region of the GSTPi gene is used in the analysis. The DNA is firstly artificially methylated at all cytosine 5 positions within the CpGs (upmethylation). The upmethylated DNA is then amplified using one round of PCR. The resultant amplificate is then divided into two samples, Sample A (the control sample) is amplified using conventional PCR. Sample B is amplified according to the disclosed method. The two samples are then compared in order to ascertain the presence of methylated CpG positions within Sample B. The comparison is carried out by means of a bisulphite treatment and analysis of the treated nucleic acids.

15

20

25

UpmethylationReagents:

30

DNA

SssI Methylase (concentration 2 units/ μ l).

SAM (S-adenosylmethionine)

4,5 µl Mss1-Buffer (NEB Buffer B+ (10 mM Tris-HCl 300 mM
NaCl, 10 mM Tris-HCl, 0.1 mM EDTA, 1 mM dithiothreitol,
500 µg/ml BSA, 50% glycerol (pH 7.4 at 25°C) pH 7.5; 10 mM
5 MgCl₂; 0,1 mg/ml BSA)

dd water (0.2 µm-filtered autoclaved, DNases, RNases,
proteases, phosphatases-free).

10 Method:

Reagents are combined and incubated at 37 degrees for 16
hours. The sample may then be stored in the refrigerator
(+4°C).

15 The upmethylated DNA is digested using the restriction
enzyme

PCR

Reagents:

20 primer I : TTCGCTGGAGTTTCGCC

primer II : GCTTGGGGGAATAGGGAG

HotStart Taq Polymerase (QIAGEN)

25 10 x PCR buffer (QIAGEN)

dNTP solution (25 mM each)

water (0.2 µm-filtered, autoclaved, DNases, RNases, pro-
teases, phosphatases-free).

30 Reagents are to be combined in a reaction solution in the
order above. The reaction solution is then cycled in a
thermocycler according to the following. An initial de-
naturation at 95°C is carried out for 15 min. This is
followed by primer annealing at 55°C for 45 sec. and
35 elongation at 72°C for 1.5 min.

The resultant reaction solution is then divided into two equal samples, A and B. Each sample is treated as below.

Sample A

- 5 Standard PCR as described above. The reaction is cycled for 40 cycles at 95°C for 1 minute, 55°C for 45 sec. and elongation at 72°C for 1.5 min.

Sample B

10 Reagents:

Human DNA (cytosine-5) Methyltransferase (New England Biolabs)

Dnmt 1 reaction buffer (50 mM TrisHCL pH7.8, 1 mM EDTA, 1 mM dithiothreitol, 7 µg/ml PMSF, 5% glycerol)

15 100 µg/ml BSA

Steps 1 to 4 are repeated 40 times:

- 20 1. DNA is precipitated and pelleted, resuspended using Dnmt1 reaction buffer, DNMT and BSA .
2. The reaction solution is incubated at 37°C.
3. DNA is precipitated and pelleted, resuspended using PCR reagents as above.
- 25 4. One cycle of PCR is carried out at 95°C for 1 minutes, 55°C for 45 sec. and elongation at 65°C for 2 min.

Sample Analysis

30 Both samples are analysed in order to ascertain their relative levels of methylation. In a first step the two samples are treated in order to distinguish between methylated and non methylated cytosines. The treatment is carried out using a solution of sodium-disulfite. The treatment converts cytosine to thymine while preserving

35 5-methyl-cytosine as cytosine. Sample A is thereby thymine rich relative to Sample B, which is relatively

cytosine rich. Following bisulphite treatment both samples are analysed by means of sequencing in order to ascertain their degree of methylation (i.e. relative concentrations of cytosine and thymine). Sequencing is carried out by means of the Sanger method using the ABI 310 sequencer (Applied Biosystems).

Claims

1. A method for the amplification of genomic DNA whereby
5 the cytosine methylation pattern of the genomic DNA
is retained in the amplificate sequence(s), said
method comprising the following steps:
(a) heating the genomic DNA to a temperature opera-
tive to cause denaturation
10 (b) cooling the denatured DNA in the presence of sin-
gle stranded oligonucleotide primers such that the
primers anneal to the DNA
(c) heating the mixture in the presence of a poly-
merase and nucleotides to a temperature such that the
15 primers are extended
(d) contacting the double stranded nucleic acid with
a methyltransferase and a methyl donor molecule under
conditions conducive to the methylation of the syn-
thesised strand such that the CpG dinucleotides
20 within the synthesised strand are methylated accord-
ing to the methylation status of the corresponding
CpG dinucleotide on the template strand thereby pre-
serving the genomic methylation pattern
(e) repeating steps A-D a desired number of times to
25 reach a desired number of nucleic acids.
2. A method according to Claim 1 wherein the methyl-
transferase is a maintenance methyltransferase.
- 30 3. A method according to Claim 1 wherein
the methyltransferase is DNA (cytosine-5) Methyl-
transferase (DNMT 1).
4. A method according to Claims 1 to 3 wherein the
35 methyl donor molecule is S-adenosylmethionine.

5. A method according to Claims 1 to 4 wherein the methyl group carries a detectable label which is incorporated into the synthesised nucleic acid strand.
- 5 6. A method according to Claims 1 to 5 wherein a plurality of primer oligonucleotides are immobilised on a solid surface.
- 10 7. A method according to Claims 1 to 5 wherein the methyltransferase is immobilised on a solid surface.
8. A method according to Claims 1 to 5 wherein the polymerase is immobilised on a solid surface.
- 15 9. A method according to Claim 1 further comprising Step (f) a treatment with an agent capable of distinguishing between methylated and unmethylated cytosine bases.
- 20 10. A method according to Claim 9 wherein the agent is a methylation sensitive restriction enzyme.
11. A method according to Claim 9 wherein the agent is a bisulphite solution.
- 25 12. A device for the methylation pattern retaining amplification of nucleic acids according to Claim 1 said device comprising two or more reaction chambers, channel means providing fluid connections between adjacent chambers and the first and last reaction chambers, temperature regulating means for controlling the temperature of each reaction chamber.
- 30 13. A device for the methylation pattern retaining amplification of nucleic acids according to Claim 1 to 6 comprising
- 35

two vessels,
a reaction chamber,
temperature regulating means for controlling the tem-
perature of the reaction chamber,
5 means for transferring liquid reagent from the first
and second vessels to the reaction chamber,
channel means providing fluid connections between ad-
jacent chambers and the first and last reaction cham-
bers
10 means for draining liquid reagents from the reaction
chamber.

14. A nucleic acid obtainable by a method according to
one of the claims 1 to 11.

15 15. A method of manufacturing a methylated nucleic acid
using a method according to one of the claims 1 to
11.

Best Available Copy




Fig.1

Best Available Copy





Fig. 2

**Fig. 3**

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/03104

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12Q B01L B01J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, MEDLINE, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	WO 99 10540 A (LOPEZ OSVALDO J ;NELSON R MICHAEL (US)) 4 March 1999 (1999-03-04) the whole document in particular page 3, line 31 -page 6, line 33 page 8, line 9 -page 9, line 19 page 14, line 34 -page 15, line 30; figure 1; example 2 --- -/-	14 1-13,15

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

21 July 2003

Date of mailing of the international search report

06/08/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mossier, B

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PRADHAN SRIHARSA ET AL: "Recombinant human DNA (cytosine-5) methyltransferase: I. Expression, purification, and comparison of de novo and maintenance methylation." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 46, 12 November 1999 (1999-11-12), pages 33002-33010, XP002248163 ISSN: 0021-9258 cited in the application	14
A	the whole document	1-13,15
X	US 6 140 110 A (HODKINSON ROGER GRANT ET AL) 31 October 2000 (2000-10-31) abstract column 3, line 35 -column 6, line 57; claim 1; figures 1-3,9	12-14
A	REIN ET AL: "Identifying 5-methylcytosine and related modifications in DNA genomes" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 26, no. 10, 1998, pages 2255-2264, XP002143106 ISSN: 0305-1048 the whole document	1-15
A	SZYF M: "THE DNA METHYLATION MACHINERY AS A THERAPEUTIC TARGET" CURRENT DRUG TARGETS, BENTHAM SCIENCE PUBLISHER,, US, vol. 1, no. 1, July 2000 (2000-07), pages 101-118, XP001122812 ISSN: 1389-4501 the whole document in particular page 101 -page 103; figures 1,2	1-15
A	WO 92 15674 A (TEPNEL MEDICAL LTD) 17 September 1992 (1992-09-17) the whole document	6-8
A	WO 02 18632 A (PIEPENBROCK CHRISTIAN ;BERLIN KURT (DE); EPIGENOMICS AG (DE); GUET) 7 March 2002 (2002-03-07) abstract	1-15

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/03104

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>HERMAN J G ET AL: "METHYLATION-SPECIFIC PCR: A NOVEL PCR ASSAY FOR METHYLATION STATUS OF CPG ISLANDS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, 1 September 1996 (1996-09-01), pages 9821-9826, XP002910406 ISSN: 0027-8424 abstract</p> <p>-----</p>	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/JP 03/03104

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9910540	A	04-03-1999	AU	9660698 A	16-03-1999
			EP	1009865 A1	21-06-2000
			WO	9910540 A1	04-03-1999
			US	6514698 B1	04-02-2003
US 6140110	A	31-10-2000	US	5912129 A	15-06-1999
			AU	3243099 A	20-09-1999
			CA	2323229 A1	10-09-1999
			WO	9945141 A1	10-09-1999
			EP	1058740 A1	13-12-2000
WO 9215674	A	17-09-1992	AU	1347392 A	06-10-1992
			WO	9215674 A2	17-09-1992
WO 0218632	A	07-03-2002	DE	10044543 A1	04-04-2002
			AU	1218702 A	13-03-2002
			AU	1218802 A	13-03-2002
			AU	4835201 A	24-09-2001
			AU	5038101 A	24-09-2001
			AU	5478801 A	23-10-2001
			AU	5479401 A	23-10-2001
			AU	7566301 A	23-10-2001
			AU	7633001 A	23-10-2001
			AU	7633101 A	23-10-2001
			AU	7637101 A	14-01-2002
			AU	7748701 A	23-10-2001
			AU	7752101 A	14-01-2002
			AU	7842001 A	07-11-2001
			AU	7970701 A	14-01-2002
			AU	8391501 A	08-01-2002
			AU	8391601 A	14-01-2002
			AU	8757501 A	08-01-2002
			AU	8757601 A	08-01-2002
			AU	8960001 A	11-12-2001
			AU	8961701 A	08-01-2002
			CA	2420840 A1	27-02-2003
			WO	0168911 A2	20-09-2001
			WO	0168912 A2	20-09-2001
			WO	0177375 A2	18-10-2001
			WO	0177164 A2	18-10-2001
			WO	0177376 A2	18-10-2001
			WO	0177377 A2	18-10-2001
			WO	0181622 A2	01-11-2001
			WO	0192565 A2	06-12-2001
			WO	0177378 A2	18-10-2001
			WO	0176451 A2	18-10-2001
			WO	0202806 A2	10-01-2002
			WO	0202807 A2	10-01-2002
			WO	0200926 A2	03-01-2002
			WO	0200927 A2	03-01-2002
			WO	0200928 A2	03-01-2002
			WO	0202808 A2	10-01-2002
			WO	0200705 A2	03-01-2002
			WO	0202809 A2	10-01-2002
			WO	0218631 A2	07-03-2002
			WO	0218632 A2	07-03-2002
			EP	1283905 A2	19-02-2003
			EP	1268855 A2	02-01-2003

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 03/03104

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0218632	A	EP 1268857 A2	02-01-2003
		EP 1272670 A2	08-01-2003
		EP 1278893 A2	29-01-2003
		EP 1274865 A2	15-01-2003
		EP 1274866 A2	15-01-2003
		EP 1294947 A2	26-03-2003
<hr/>			